[公司]华邦健康2024年度暨2025年第一季度业绩说明会举办：经营韧性持续凸显 不断夯实核心竞争力

Group 1 - The core viewpoint of the articles highlights the resilience and growth of the company, with a revenue of 11.665 billion yuan in 2024, maintaining over 10 billion yuan for seven consecutive years, despite intensified industry competition [2] - In the first quarter of 2025, the company achieved a nearly 20% year-on-year increase in net profit attributable to shareholders, with a gross profit margin improvement to 37.12%, indicating significant enhancement in profitability [2] - The company has made notable advancements in its pharmaceutical segment, including the approval of the first domestic generic product for psoriasis treatment, marking a significant breakthrough in the field [2] Group 2 - The medical business segment is still in the development phase, with revenue from Songshan Hospital reaching 678 million yuan in 2024, and other hospitals generating a combined revenue of 351 million yuan, showing a stable upward trend [3] - The tourism segment leverages core resources from listed company Lijiang Co. and NEEQ-listed Qinling Tourism, with operations across five major 5A scenic areas, focusing on enhancing visitor service quality and increasing tourist reception [3] - The company plans to continue executing its "big health" development strategy, concentrating on pharmaceuticals and medical services, while enhancing its full industry chain development model [3]